Popular opinion is that two big shifts have changed the game for bioinformatics. The first is a technology development—single cell ‘omics—that began just over 10 years ago, the other is a more recent move to a new model of drug discovery that looks to leverage the vast amounts of human genetic data now being generated in support of precision medicine.
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-resolution and comprehensive reference maps of all human cells within our reach. Paradigm4’s Marilyn Matz, CEO and cofounder, and Dr Zachary Pitluk, VP of Life Sciences and Healthcare, report
Paradigm4’s Marilyn Matz reflects on the understanding complex biological phenomena has required concurrent advances in experimental methods and computing power.
